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Most human herpesviruses, including Epstein-Barr virus (EBV), express a protein which functions primarily
as an mRNA export factor. Previously, we deleted the gene for the Epstein-Barr virus mRNA export factor EB2
from the EBV genome and then introduced the mutated genome into 293 cells. Using a transcomplementation
assay in which ectopic expression of the transcription factor EB1/ZEBRA was sufficient to induce the EBV
productive cycle, we showed that Ori-Lyt-dependent replication of the EBV DNA occurs in the absence of EB2,
indicating that EB2 is not essential for the expression and export of early mRNAs. However, in the absence of
EB2, no infectious viral particles are produced (H. Gruffat, J. Batisse, D. Pich, B. Neuhierl, E. Manet,
W. Hammerschmidt, and A. Sergeant, J. Virol. 76:9635–9644, 2002). In this report, we now show that EB2 is
essential for the nuclear export of most, but not all, late mRNAs produced from intronless genes that translate
into proteins involved in intranuclear capsid assembly and maturation. As a consequence, we show that EB2
is essential for the proper assembly of intranuclear capsids. Interestingly, the late BLLF1 gene contains an
intron, and both unspliced and spliced mRNAs must be exported to the cytoplasm to be translated into gp350
and gp220, respectively (M. Hummel, D. A. Thorley-Lawson, and E. Kieff, J. Virol. 49:413–417, 1984). Our
results also demonstrate that although BLLF1 spliced mRNAs are exported to the cytoplasm independently of
EB2, EB2 is essential for the nuclear export of unspliced BLLF1 mRNA. In the same assay, herpes simplex
virus 1 ICP27 completely inhibited the nuclear export of BLLF1 spliced mRNAs whereas unspliced BLLF1
mRNAs were exported, confirming that in a physiological assay, ICP27 inhibits splicing.
The Epstein-Barr virus (EBV) is a human gammaherpesvirus
that infects over 90% of the adult human population. After the
primary infection, EBV persists lifelong in resting recirculating
memory B lymphocytes, which express either one viral gene or
none (2). Persistence is strongly linked to certain EBV-associated
malignancies, i.e., Burkitt’s lymphoma, nasopharyngeal carci-
noma, Hodgkin’s disease, gastric cancer, posttransplant lympho-
proliferative disorders, AIDS-associated lymphomas, and leio-
myosarcomas (reviewed in reference 42). The association of EBV
with cancers is strengthened by the fact that in vitro, EBV drives
resting B lymphocytes to proliferate as activated lymphoblasts. In
such proliferating blasts, the EBV transcriptome is restricted
to few genes defining a type III latency, with no expression of
the genes required for a complete productive cycle (reviewed
in reference 34). However, in vivo, the EBV productive cycle
occurs, since infectious viruses are found in the saliva of
healthy carriers (13). Recently, in vivo reactivation has been
linked to the terminal differentiation of infected B cells into
plasma cells, but the signals and the molecular mechanisms
that trigger the switch from latency to the productive cycle are
as yet unknown (29). The productive cycle can be induced,
however, in blasts latently infected in vitro, by a variety of
treatments such as TPA (46), transforming growth factor  (6),
and anti-surface immunoglobulin (41), without inducing ter-
minal differentiation of EBV-infected B cells into plasma cells.
These in vitro treatments induce the transcription of the two
immediate-early genes, BZLF1 and BRLF1 (reviewed in ref-
erence 1), whose products are transcription factors called, re-
spectively, EB1 (7) or ZEBRA (14) and R (17). The EB1/
ZEBRA viral factor activates the transcription of all the early
genes, including BRLF1 (7), some of them being essential to
viral DNA replication, which is a prerequisite for the expres-
sion of most late genes, DNA encapsidation, and infectious
virion production (reviewed in reference 26).
Not all the early gene products are involved in DNA repli-
cation. The BSLF2/BMLF1 early gene encodes a posttran-
scriptional regulatory protein originally called EB2 (7) but
later renamed Mta (12) or SM (8). The BSLF2/BMLF1 open
reading frame (ORF) is conserved in other human herpesvi-
ruses (HHVs), suggesting a conserved function: the herpes
simplex virus 1 (HSV-1) ICP27 protein (37), the human cyto-
megalovirus (CMV) UL69 protein (30), and the Kaposi’s sar-
coma-associated virus (KSHV [HHV-8]) ORF57 protein (31).
HSV-1 ICP27, EBV EB2, and HHV-8 ORF57 are nuclear
proteins that have properties of mRNA nuclear export factors.
They shuttle between the nucleus and the cytoplasm in a
CRM1-independent manner (11, 28, 30). They bind to RNA in
vitro and in vivo (18, 32), interact with essential components of
the nuclear export pathway RNA export factor (REF)/Aly
(scYra1) and transport activating protein (TAP)/p15 (scMex67p/
Mtr2p) (19, 28, 31), and induce cytoplasmic accumulation of
some viral and cellular mRNAs (4, 27, 36). In line with the
above-described results, deletion of the major part of the
BSLF2/BMLF1 gene in the EBV genome abolished the pro-
duction of infectious viral particles (15), demonstrating that
EB2 is an essential viral factor whose function cannot be
transcomplemented by cellular factors. Moreover, EB2 did not
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efficiently complement ICP27 when inserted into an ICP27-
null mutant (3), and neither ICP27 nor UL69 transcomple-
mented EB2 in inducing the production of infectious virions
from the EB2-null mutant (15), strongly suggesting a specific
viral function for these factors.
Using our EB2 deletion virus, we show here that EB2 is
required for the nuclear export of most late mRNAs translated
into proteins required for the maturation and assembly of viral
capsids. Accordingly, we show that, in the absence of EB2, the
newly replicated viral DNA is not protected against DNase I
digestion in the nuclei, strongly suggesting that it is not prop-
erly encapsidated. However, not all late mRNAs are exported
by EB2. Exceptions include the BALF4 and the BBRF1
mRNAs. In addition, we show that cytoplasmic accumulation
of the unspliced form of BLLF1 mRNA, which encodes the
gp350 protein, is strongly dependent on EB2. However, the
spliced version of this mRNA, which encodes for gp220 pro-
tein, accumulates in the cytoplasm, even in the absence of EB2.
In our transcomplementation assay, ICP27 also exported some
unspliced BLLF1 mRNA, but as expected, it abolished the
appearance of spliced BLLF1 mRNA in the cytoplasm.
MATERIALS AND METHODS
Viral DNA analysis. 293BMLF1-ko cells were transfected with an EB1 expres-
sion vector to activate the EBV productive cycle and transcomplemented or not
transcomplemented with an EB2 expression vector. At 48 h after transfection,
the medium was removed, and the cells were resuspended in Tris-buffered saline
(137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4, 5.5 mM glucose, 25 mM Tris-HCl,
pH 7.4) and divided into two equal samples, which were then used to prepare
total cellular and DNase-resistant (encapsidated) DNAs. The cells from both
samples were pelleted and resuspended in 184 l of reticulocyte standard buffer
(10 mM Tris-HCl [pH 7.5], 10 mM KCl, 1.5 mM MgCl2) containing 0.5% NP-40.
An equal volume of 2 CLB (20 mM Tris-HCl [pH 7.5], 2 mM EDTA, 1.2%
sodium dodecyl sulfate, 1 mg/ml of proteinase K) was added either immediately
(total cellular DNA) or after incubation in the presence of 200 g of DNase I/ml,
with occasional mixing, for 20 min at 37°C (encapsidated DNA). After the
addition of proteinase K, all samples were incubated for 1 h at 37°C, extracted
sequentially with phenol and chloroform, and precipitated with ethanol, and then
the nucleic acids were redissolved in 10 mM Tris-HCl (pH 7.5)–1 mM EDTA
containing 5 g of RNase A/ml and 50 U of RNase T1/ml. Gel analysis of the
DNAs was performed as follows. Samples of DNA corresponding to the yield
from 4.105 cells were cleaved with BamHI enzyme, and the resulting fragments
were separated by agarose gel electrophoresis, transferred to a Hybond-N mem-
brane (Amersham), and detected by hybridization to 32P-labeled BRRF1 probes.
As a control for the amount of DNA loaded on the gel, a 32P-labeled -globin
probe was also used. Southern blots were analyzed using a PhosphorImager.
Cell lines and transfections. The 293BMLF1-ko cell line has been described
extensively previously (15). Cells were grown in RPMI 1640 medium supple-
mented with penicillin, streptomycin, and 10% fetal calf serum (Invitrogen). A
total of 5.106 cells were transfected by electroporation (Bio-Rad GenePulser)
(210 V, 950 F) with 10 g of each vector. HeLa cells were grown in Dulbecco’s
modified Eagle medium supplemented with penicillin, streptomycin, and 5%
fetal calf serum (Invitrogen). Transfections were performed using calcium phos-
phate with 15 g of total DNA (1 g of each vector and pUC18 to 15 g), as
described previously.
Expression vectors. pCMV-BZLF1 contains the BZLF1 cDNA coding for the
EB1 protein cloned under the control of the CMV promoter in the pRc-
CMVneo vector (39). pCi-FlagEB2 contains the BSLF2-BMLF1 cDNA coding
for the EB2 protein cloned under the control of the CMV promoter in the pCi
vector (Promega). The Flag EB2 protein expressed from this vector has been
tagged at its N terminus with the Flag epitope which can be detected by the M2
monoclonal antibody (Sigma reference F3165) (19). The ICP27- and UL69-
expressing vectors were kindly provided by, respectively, A. Epstein and
T. Stamminger (30). pCi-Flag-BdRF1i and pCi-Flag-BFRF3i contain, re-
spectively, the BdRF1 and the BFRF3 ORFs obtained by reverse transcription-
PCR (RT-PCR) with primers that are described in Table 1. In pCi-Flag-BdRF1-i
or pCi-Flag-BFRF3-i, the original pCi intron has been deleted by digestion with
Afl II. Plasmids used for transfection were prepared by the alkaline lysis method
and purified through two CsCl-ethidium bromide gradients.
Western blotting analysis. Cells were collected by centrifugation, lysed on ice
for 30 min in 100 l of HNTG buffer (50 mM HEPES [pH 7.5]; 150 mM NaCl;
1% Triton; 10% glycerol; 1 mM EDTA; 1 mM phenylmethylsulfonyl fluoride).
Proteins were separated on 10% sodium dodecyl sulfate–polyacrylamide elec-
trophoresis gels and then transferred to a nitrocellulose membrane by electro-
blotting (Hybond-ECL; Amersham Biosciences). The membranes were incu-
bated with either the anti-protease monoclonal antibody (8E9E11) (a gift from
P. Morand) or the rat monoclonal antibody anti-BFRF3 (OT15E) (44). Mem-
branes were also incubated with an anti-EB2-specific polyclonal antibody (dilu-
tion, 1:500) (15). Goat anti-mouse or goat anti-rabbit horseradish peroxidase
conjugate (Amersham) was used at a dilution of 1:5,000 as a secondary antibody.
For immunoblot detection, the ECL system (Amersham) was used.
Immunofluorescence assay. Cells were seeded on polylysine pretreated glass
coverslips and then transfected with the appropriate plasmid. At 48 h after
transfection, cells were washed twice with phosphate-buffered saline and fixed
with 4% paraformaldehyde, and then indirect immunofluorescence was per-
formed as described before (11). The glass coverslips were incubated with either
the anti-BdRF1 monoclonal antibody (OT41A) (45) or the anti-BcLF1 mono-
clonal antibody (MAB8185 Chemicon) or the anti-gB monoclonal antibody
(MAB8184 Chemicon).
RNA extraction and RT-PCR analysis. Transfected cells were washed twice
with phosphate-buffered saline, and cytoplasmic RNAs were extracted as previ-
ously described (16). Briefly, cells were resuspended in 475 l of lysis buffer
(10 mM Tris-HCl [pH 7.8], 10 mM NaCl, 2 mM MgCl2, 5 mM dithiothreitol),
and after 5 min on ice, 25 l of 10% NP40 was added. After centrifugation to
collect the nuclei (2 min, 1,200 rpm, 4°C), cytoplasmic RNAs contained in the
supernatant were purified by phenol chloroform extraction and ethanol precip-
itation. Nuclear RNAs were purified from the isolated nuclei with TRIzol re-
agent (Invitrogen). Then, a DNase treatment master mix containing AMV/RT
reaction buffer (Biolabs), MgSO4 (2.5 mM final concentration), and 1 U DNase/
RNase free (Roche Diagnostics) was prepared to digest any DNA contamination
from RNA preparations for 1 h at 37°C. This was followed by 15 min of DNase
inactivation at 65°C. Reverse transcription were performed with 2 g of purified
nuclear or cytoplasmic RNA by use of Stratascript reverse transcriptase (Strat-
agene) and 0.5 g of oligo(dT18) (Roche Diagnostics) for 1 h at 42°C. PCRs were
performed using a Taq core kit (Q-Biogen) in the presence of [32-P]dCTP
(0.1 Ci), with a set of specific primer pairs (see Table 1), on various amounts of
the RT reaction mixtures (0.2, 0.4, 1 or 2 l) to have a linearly increasing signal
after 25 PCR cycles. The PCR-amplified fragments were then analyzed on 2%
agarose gels and autoradiographed. Each of the PCR-amplified bands was sub-
sequently quantified with a Storm PhosphorImager. To control our RT-PCR
experiments, we evaluated the endogenous expression of -actin mRNA by
RT-PCR (see Table 1). Amplification of a 690-bp DNA fragment corresponding
to -actin mRNA showed that no DNA contamination was present in our RNA
preparations. We have also used RT-PCR to look for the presence of the U6
snRNA in the nuclear and cytoplasmic extracts to control for the purity of our
cytoplasmic RNAs.
RESULTS
EB2 is encoded by an extension of the BSLF2 ORF and not
by the BMLF1 ORF. It has been reported that the EBV BSLF2
and BMLF1 ORFs are joined to encode a protein originally
called EB2 (7) and later renamed Mta (12) or SM (8)
(Fig. 1A). cDNA cloning allowed us to characterize two cyto-
plasmic mRNAs covering the BSLF2/BMLF1 region (5), one
unspliced and one spliced. Sequencing of the cDNAs demon-
strated that in the spliced mRNA, the BSLF2 ORF termina-
tion codon is deleted, and that the BSLF2 ORF starting at
position 84228 is prolonged until the next termination codon,
at position 82745 (B95-8 sequence), encoding a putative
polypeptide of 479 amino acids (aa) (Fig. 1A). Since no inter-
nal ribosomal entry site has been described upstream of the
BMLF1 ORF, only the BSLF2 ORF should be used in un-
spliced mRNAs, thus encoding a putative polypeptide of 38 aa.
In addition, in the unspliced mRNA, the BSLF2 ORF and the
BMLF1 ORF are not in frame. The polypeptide encoded by
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the BMLF1 ORF should be 438 aa long. To confirm that the
extended BSLF2 ORF from the spliced mRNAs encodes EB2,
EB2 expression was induced in Raji cells by treatment with TPA/
butyric acid (BA) or by transfecting either a cDNA corresponding
to the spliced RNA (paacEB2; Fig. 1B) or a truncated cDNA
corresponding to a putative mRNA containing only the BMLF1
ORF (paacBMLF1; Fig. 1B). As shown in Fig. 1C, a polyclonal
antibody raised against the EB2 protein detected a polypeptide of
about 60 kDa in TPA/BA-induced Raji cells (Fig. 1C, lane 2). A
polypeptide with the same apparent molecular weight was de-
tected in Raji cells transfected with paacEB2 (Fig. 1C, lane 3),
while a polypeptide of about 46 kDa was detected in Raji cells
transfected with paacBMLF1 (Fig. 1C, lane 4). This clearly
demonstrated that EB2 is the product of the extended BSLF2
ORF and that the BMLF1 ORF exists only theoretically.
EB2 is essential for the proper encapsidation of the EBV
genome. We have previously reported the generation of an
EBV mutant in which the BSLF2/BMLF1 gene encoding the
EB2 protein has been partly deleted. The mutated viral ge-
nome was introduced into 293 cells, and then a clonal popu-
lation called 293BMLF1-ko was selected (15). We reported that
such cells produced infectious EBV particles only when trans-
fected with both an EB1 and an EB2 expression vector (15). In
this transcomplementation assay, EBV DNA replication oc-
curs in the absence of EB2, but there is no production of
infectious viral particles, suggesting that the newly replicated
intranuclear EBV DNA is either poorly encapsidated or im-
properly encapsidated in the absence of EB2. Herpesvirus en-
capsidation proceeds by a complex mechanism in which cleav-
age of viral DNA concatemers into monomeric units is tightly
coupled with their insertion into the procapsid (for a review,
see reference 20). The intranuclear encapsidated viral DNA is
protected against the action of exogenously added DNase I.
This property was used to test whether the replicated intranu-
clear viral DNA was encapsidated in the absence of EB2.
293BMLF1-ko cells were mock transfected, transfected with an
EB1 expression vector, or transfected with both an EB1 and an
EB2 expression vector. Three days after transfection, nuclei
were prepared, and the DNA was extracted, digested with
BamHI, and analyzed by Southern blotting using an EBV
BRRF1 probe. As shown in Fig. 2, the intranuclear resident
viral DNA (lane 1) was amplified when the cells were trans-
TABLE 1. List of primers used
Gene and primer Sequence (5 3 3) B95-8 relative position
U6 snRNA
Forward CGCTTCGGCAGCACATATAC
Reverse AAAATATGGAACGCTTCACGA
-Actin
Forward GCTGCGTGTGGCTCCCGAGGAG
Reverse ATCTTCATTGTGCTGGGTGCCAG
BALF4
Forward GGAGTCGTAGGCAAATTGGA 157922–157941
Reverse TCAAGAACCTGACGGAGCTT 158125–158145
BBRF1
Forward AAGATCTGCCAGCTCCTGAA 115017–115036
Reverse ATGAACTCCTCCACCACGTC 115197–115216
BcLF1
Forward GACAATTATCAAAAAACCACC 133313–133332
Reverse GGTGCAGTTTGTAGTG 133528–133543
BDLF1
Forward CAGATTTGAAAGTGGTAGTGTC 133283–133301
Reverse TTATCTTAACCAGCAAGTGGCCG 132400–132422
BdRF1/BVRF2
Forward CACTATCAGGTAACGCAGGAG 148710–148728
Reverse TCAAGCCAGCGTTTATTCAGC 149723–149744
BFRF3
Forward GGGAGGCTCAAAGAAGTTACCTG 61628–61650
Reverse ATGAAGAAACAGAGGGGGTCGC 61882–61903
BFRF3 (for cloning)
Forward GCCCAGATCTCGAGCAGCACGCCGGCTGCCC 61510–61524
Reverse GCCCTCTAGACTACTGTTTCTTACGTGCCCCGCG 62014–62037
BLLF1
Forwarda TGTGCTGATAGAGGCTGGTG 90018–90037
Reverseb TGACACCAAGTCCATCTCCA 90672–90691
BMRF1
Forward CCAGACATACGGTCAGTCCATCTC 80881–80904
Reverse TGCTTCACTTTCTTGGGGTGC 81071–81091
BORF1
Forward GCCCCTCGAGCAAGGTCCAGGGGTCCGTCG 75242–75259
Reverse GCCCTCTAGAGAATCACCTCCCAGTCAGAG 76308–76333
BVRF1
Forward GGGCAACCTGAACTTTACCA 145991–146010
Reverse CGGCGATGATTTTCTCTAGG 146219–146238
a Primer 299.
b Primer 300.
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fected with an EB1 expression plasmid (lane 2); as already
shown, EB2 enhanced the replication efficiency (lane 3). As a
control for the amount of DNA loaded on the gel, the South-
ern blot was incubated with a -globin probe. The result
showed that, indeed, in each lane a comparable amount of
total DNA was used. We next asked whether the replicated
DNA was encapsidated. When intact nuclei were treated with
DNase I, the resident intranuclear viral DNA was completely
digested (Fig. 2, lane 4), as well as the viral DNA whose
replication was induced by EB1 (Fig. 2, lane 5). However, in
the presence of EB1 and EB2, conditions required for the
production of infectious EBV particles by 293BMLF1-ko cells
(15), part of the intranuclear replicated viral DNA was pro-
tected against digestion by DNase I (Fig. 2, lane 6). These
results strongly suggest that EB2 is essential for the proper
encapsidation of replicated intranuclear viral DNA, probably
through its action on the export of some late mRNAs.
EB2 is essential for the production of viral capsid proteins.
We reasoned that EB2 could be essential for the nuclear ex-
port of viral mRNAs translated into proteins required for the
assembly and maturation of virions. Therefore, we looked at
the EBV genes encoding capsid components or capsid assem-
bly factors. EBV protein composition has not been systemati-
cally studied, as in the case of HSV-1, except for the glyco-
proteins. EBV protein annotations have usually been based on
DNA sequence homology to a characterized herpesvirus ORF,
FIG. 1. EB2 is the product of the BSLF2/BMLF1 gene. (A) Schematic structure of the BSLF2 and BMLF1 open reading frames on the EBV
genome. The relative positions of the initiation codons (ATG), stop codons, the borders of the intron, and the putative ORFs are given according
to the sequence of the B95-8 viral strain. (B) Schematic representation of the expression vectors used. The cDNA sequence from the BSLF2/
BMLF1 gene was inserted in the paac vector to generate the paacEB2 vector. paacBMLF1 contains the BMLF1 ORF. CMV, cytomegalovirus
promoter. (C) Western blot analysis of Raji cells transfected with the expression vector paacEB2 (lane 3) or paacBMLF1 (lane 4) or induced into
the productive cycle by treatment with TPA/BA (lane 2). A rabbit polyclonal serum directed against the EB2 protein was used.
FIG. 2. Packaging of the EBV DNA in 293BMLF1-ko cells.
293BMLF1-ko cells were induced into the productive cycle by transfec-
tion with an EB1 expression vector and transcomplemented or not
transcomplemented with an EB2 expression vector as indicated above
the lanes. Total (/) and DNase-resistant (DNase I) DNAs were pre-
pared 48 h after transfection. Samples were cleaved with BamHI, and
the fragments were resolved by electrophoresis through a 0.8% aga-
rose gel, transferred to a nylon membrane, and hybridized to
32P-labeled BRRF1 DNA. The numbers below the lanes containing
total DNA indicate the ratios of newly replicated viral DNA quantified
after PhosphorImager exposure of the membrane. As a control for the
amount of DNA loaded on the gel, the Southern blot was also incu-
bated with a -globin probe.
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with verification for EBV in specific instances. Accordingly,
EBV BcLF1, BDLF1, BORF1, BFRF3, BVRF2, BdRF1,
BBRF1, and BVRF1 ORFs are likely to encode, respectively,
the major capsid protein (MCP), minor capsid protein (mCP),
the mCP-binding protein (mCP-BP), the smallest capsid
protein (sCP), the protease (Pr), the protease-assemblin (Pr/
AP), the portal protein, and the capsid-associated cork
(Table 2) (10, 25). On the basis of this nomenclature we have
used RT-PCR to look for the expression of the corresponding
mRNAs in 293BMLF1-ko cells that were mock transfected,
transfected with an EB1 expression vector, or transfected with
both an EB1 and an EB2 expression vector. Cytoplasmic
mRNAs were extracted from the transfected cells, reverse
FIG. 3. The EB2 protein induces the cytoplasmic accumulation of specific mRNA encoding EBV capsid protein. (A) Control of the purity of
our cytoplasmic (Cyto) RNA fraction: RNA from 293BMLF1-ko cells transiently transfected with a control vector or expression plasmids encoding
proteins as indicated at the top of the figure were submitted to RT-PCR analysis using specific primers to detect the U6 snRNA. nucl, nuclear.
(B) RNA from 293BMLF1-ko cells transiently transfected as indicated at the top of the figure were submitted to RT-PCR analysis using specific
primers to detect the -actin cellular mRNA or EBV late mRNA encoding BcLF1, BDLF1, BORF1, BFRF3, BdRF1, BBRF1, and BVRF1. The
PCR products were loaded on a 2% agarose gel and visualized by ethidium bromide staining. (C) Example from the results of our semiquantitative
experiments done using the BFRF3 mRNA. Each PCR (25 cycles) was done with various amounts of RT product and in the presence of
[-32P]dCTP. The gel was quantified after PhosphorImager exposure. (D) Western blot analysis of the 293BMLF1-ko cells transiently transfected with
a control vector or expression plasmids encoding proteins as indicated at the top of the figure. The membranes were incubated with either an
anti-protease or an anti-BFRF3 monoclonal antibody. (E) Expression of the BdRF1 and BcLF1 proteins was monitored by immunofluorescence.
The 293BMLF1-ko cells were transiently transfected with expression plasmids encoding proteins as indicated on the left of the figure. After the cells
were labeled with the appropriate antibody, they were stained with bisBENZIMIDE to label their nuclei and observed on a UV fluorescence
microscope. The nuclei stained blue; the BdRF1 and BcLF1 proteins stained red.
TABLE 2. EBV genes and their encoded proteins involved in the
capsid structure
EBV
gene HSV-1 homologue Protein description MW
a
BcLF1 UL19 (VP5) Major capsid protein (MCP) 155
BDLF1 UL18 (VP23) Minor capsid protein (mCP) 30
BORF1 UL38 (VP19C) Minor capsid protein-BP
(mCP-BP)
40
BFRF3 UL35 (VP26) Smallest capsid protein (sCP) 18
BVRF2 UL26 (VP24) Protease (Pr) 26
BdRF1 UL26.5 (VP22a) Protease-assemblin (Pr/AP) 80
BBRF1 UL6 Portal 68
BVRF1 UL25 Capsid-associated “Cork” 58
a MW, molecular weight.
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transcribed, and quantified by PCR using different primers
specific for the genes studied (see Table 1). We also analyzed
by RT-PCR the presence of U6 snRNA, which cannot be
exported, to control the purity of our cytoplasmic RNAs. As
shown in Fig. 3A, although U6 snRNA was mainly detected in
the nuclear fraction, our cytoplasmic RNAs contained some
U6 snRNA, likely due to nuclear leakage during nuclear-cyto-
plasmic fractionation. -Actin RNA was used to confirm that
the same amount of RNA was used in each RT-PCR experi-
ment and that there was no DNA contaminating the RNA
preparation (Fig. 3B). In mock-transfected 293BMLF1-ko cells,
the proteins necessary for viral capsid formation are not ex-
pressed; accordingly, their corresponding mRNAs were not
detectable by RT-PCR (Fig. 3B, lanes 1). In 293BMLF1-ko cells
transfected with an EB1 expression vector, the RNAs synthe-
sized from the capsid genes were detected by RT-PCR to
various degrees ranging from not detected (BcLF1) to weakly
detected (BDLF1, BFRF3, BdRF1/BVRF2, and BVRF1) and
clearly detected (BORF1 and BBRF1) (Fig. 3B, lanes 2).
BcLF1 expression was not detected even when more RT prod-
uct was used in the PCR (data not shown). As expected, in
293BMLF1-ko cells expressing both EB1 and EB2, there was an
increase in the cytoplasmic accumulation of all the mRNAs
encoding the capsid proteins except for the BBRF1 mRNA
(Fig. 3B, lanes 3). Each PCR was done with various amounts of
RT products, and linearly increasing signals were observed.
Such semiquantitative analysis is presented for the BFRF3
mRNA (Fig. 3C) and for the BALF4 mRNA (Fig. 4). The PCR
results presented in Fig. 3B are in the linear range, since they
correspond to 1 l of cDNA and 25 cycles of PCR. The above-
described results were also confirmed by Western blotting or
indirect immunofluorescence at the protein level (Fig. 3D and
3E). Hence, the viral protease (product of the BVRF2 gene)
and the smallest capsid protein (BFRF3 protein) were de-
tected by Western blotting with specific antibody only when
EB2 was expressed in 293BMLF1-ko cells (Fig. 3D). Similarly,
the BdRF1 protein (assemblin) and the BcLF1 protein (MCP)
were detected by immunofluorescence in 293BMLF1-ko cells
only when the EB2 protein was expressed (Fig. 3E). Taken
together, the above-described results demonstrate that EB2 is
indirectly—probably through its mRNA export function—nec-
essary for EBV capsid formation.
Not all late mRNAs are EB2 targets. As shown above, in
293BMLF1-ko cells, EB2 increases the cytoplasmic accumulation
of all EBV late mRNAs encoding the proteins required for
assembly and processing of the viral capsid except BBRF1
mRNA. We therefore asked whether or not EB2 increased the
cytoplasmic accumulation of another late mRNA essential for
the formation of infectious virions. To answer this question, we
analyzed the cytoplasmic accumulation of the mRNA encoding
the viral glycoprotein gB (or gp110), the product of the BALF4
gene. 293BMLF1-ko cells were transfected as described above.
Three days after transfection, cytoplasmic mRNAs were iso-
lated and reverse transcribed and increasing amounts of the
RT products were analyzed by PCR. As shown in Fig. 4A, the
PCR signals increased linearly with the amount of RT product
used. As expected, the BALF4 gene was not expressed in
mock-transfected cells (lanes 1, 4, 7, and 10), and EB1 induced
the expression of the BALF4 mRNA (lanes 2, 5, 8, and 11).
However, EB2 had no effect on the amount of BALF4 mRNA
exported to the cytoplasm (lanes 3, 6, 9, and 12). This was also
seen at the level of gp110 expression in cells (Fig. 4B). The
above-described results confirm that EB2 is not required for
the export of all late mRNAs.
EBV EB2 and CMV UL69 export unspliced BLLF1 mRNA.
Most of the EBV and HSV1 late genes are intronless. It has
been suggested that, among other functions, EBV EB2 and
HSV1 ICP27 have a unique function in the viral productive
cycle that cannot be transcomplemented by cellular factors,
i.e., to export mRNAs generated from intronless genes (11, 28,
36). In addition, EB2 exports unspliced mRNAs of different
origins (4, 11), and ICP27 inhibits splicing (reference 38 and
references therein). In this context, it was interesting to ana-
lyze the cytoplasmic accumulation of the BLLF1 mRNA be-
cause, as shown in Fig. 5A, the EBV BLLF1 late gene contains
an intron. Both spliced and unspliced mRNAs produced by
facultative splicing are exported to the cytoplasm and are
translated in 100-kDa and 130-kDa proteins, precursors of
the EBV glycoproteins gp220 and gp350, respectively (24). We
therefore looked at the cytoplasmic accumulation of the
FIG. 4. Cytoplasmic accumulation of late BALF4 mRNA is EB2
independent. (A) RNA from 293BMLF1-ko cells transiently transfected
with a control vector or expression plasmids encoding proteins as
indicated at the top of the figure were submitted to RT-PCR analysis
using specific primers to detect the BALF4 mRNA. The PCR
(25 cycles) was done with various amounts of RT product and in the
presence of [-32P]dCTP. The PCR products were loaded on a 6%
polyacrylamide gel and visualized by autoradiography. (B) Expression
of the BALF4 protein (gp110) was monitored by immunofluorescence.
The 293BMLF1-ko cells were transiently transfected with expression
plasmids encoding proteins as indicated on the left of the figure. After
the cells were labeled with the anti-BALF4 antibody, they were ob-
served on a UV fluorescence microscope. The BALF4 protein stained
red.
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spliced and unspliced BLLF1 late mRNAs to analyze the func-
tions of EB2 and ICP27. As shown in Fig. 5B, BLLF1 mRNAs
were not expressed in mock-transfected 293BMLF1-ko cells
(Fig. 5B, lane 1). Interestingly, only the spliced BLLF1
mRNAs accumulated efficiently in the cytoplasm of
293BMLF1-ko cells transfected with an expression vector for
EB1 (Fig. 5B, lane 2), whereas in 293BMLF1-ko cells transfected
with vectors expressing EB1 and EB2, both spliced and un-
spliced BLLF1 mRNAs were exported to the cytoplasm (Fig.
5B, lane 3). It is noteworthy that EB2 had no effect on the
cytoplasmic accumulation of spliced BLLF1 mRNAs (Fig. 5B,
lane 3), whereas, and as expected, coexpression of EB1 and
ICP27 was followed by a near-complete absence of cytoplasmic
spliced BLLF1 mRNAs (Fig. 5B, lane 4). However, some
unspliced BLLF1 mRNAs accumulated in the cytoplasm of
293BMLF1-ko cells transfected with expression vectors for
EB1 and ICP27 (Fig. 5B, lane 4). Since the human cytomeg-
alovirus UL69 appears to be an mRNA export factor (15,
30), we also looked at its effect on the export of BLLF1
mRNAs. As shown in Fig. 5B, lane 5, UL69 had no effect on
the cytoplasmic accumulation of spliced BLLF1 mRNAs but
induced the nuclear export of unspliced BLLF1 mRNAs. Sev-
eral low-abundance forms of unspliced BLLF1 migrating with
a lower molecular weight were observed on the gel; their pres-
ence was probably due to the fact that the amplified fragment
is constituted by several repeats. Taken together, these results
suggest that UL69 has functions similar to that of EB2 and
ICP27, i.e., facilitating the export of unspliced mRNAs, but
these three proteins probably act by a different mechanism.
For example, ICP27, but not EB2 and UL69, inhibits splicing.
The EB2-dependent nuclear export of intronless EBV
mRNAs can be reproduced in a transient expression assay,
with nonreplicating plasmids. As shown above, EB2 increases
the export of some EBV mRNAs generated from late intron-
less genes but has no effect on the export of mRNAs generated
from genes containing a functional intron. To rule out any
putative effect of EBV DNA replication and as a first attempt
to determine what makes an mRNA an EB2 target, we cloned
the BFRF3 and the BdRF1 ORFs under the control of the
CMV promoter in nonreplicative plasmids. Two types of con-
structions were made. In the first type, BFRF3 and BdRF1
were expressed from precursor mRNAs containing an artificial
intron localized in the 5 untranslated region (BFRF3i and
BdRF1i, respectively). In the second type, BFRF3 or BdRF1
was expressed from intronless precursor mRNAs (Fig. 6A). In
all these constructions, the transcripts are initiated at the CMV
promoter and contained only the viral ORF; viral RNA se-
quences corresponding to 5 methylated cap the 5 untrans-
lated region, the 3 untranslated region, and the cleavage-
polyadenylation signal were excluded. As shown in Fig. 6B,
only small amounts of BFRF3-i mRNA (lane 8) and no
FIG. 5. Expression of the late BLLF1 gene. (A) Schematic represen-
tation of the BLLF1 gene. 1, mRNA initiation site; PolyA, polyadenyl-
ation signal. From the BLLF1 gene, by alternative splicing, two mRNAs
are synthesized encoding, respectively, the gp350 and gp220 proteins. 299
and 300 are the primers used for the PCR. (B) RNA from 293BMLF1-ko
cells transiently transfected with a control vector or expression plasmids
encoding proteins as indicated at the top of the panel were submitted to
RT-PCR analysis using specific primers (299 and 300) to detect the two
BLLF1 mRNAs. The PCR products were loaded on a 2% agarose gel and
visualized by ethidium bromide staining.
FIG. 6. The EB2-dependent cytoplasmic accumulation of intron-
less EBV mRNAs can be reproduced in a transient expression assay
with nonreplicating plasmids. (A) Schematic representation of the
reporter plasmids used. The BFRF3 or BdRF1 ORF was cloned under
the control of the CMV promoter into the pCI vector containing or not
containing an artificial intron. (B) RNA from HeLa cells transiently
transfected with a control vector or expression plasmids encoding
proteins as indicated at the top of the panel were submitted to RT-
PCR analysis using specific primers to detect the BFRF3 or the BdRF1
mRNA. The PCR products were loaded on a 2% agarose gel and
visualized by ethidium bromide staining.
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BdRF1-i mRNA (lane 3) accumulated in the cytoplasm of
transiently transfected HeLa cells. However, in the presence
of EB2, the amount of cytoplasmic BdRF1-i (lane 5) and
BFRF3-i (lane 10) mRNAs strongly increased. As expected,
BdRF1i (lane 2) and BFRF3i (lane 7) mRNAs were effi-
ciently exported to the cytoplasm and EB2 did not significantly
affect the nuclear export of these mRNAs (compare lanes 2 to
4 and lanes 7 to 9). These results confirm that EB2 has no
effect on the nuclear export of mRNAs generated from intron-
containing genes. In contrast, EB2 increases the export of
mRNAs generated from late viral intronless genes, an effect
independent of 5 and 3 noncoding viral RNA sequences. In
addition, these results show that the effect of EB2 observed on
the late mRNAs is direct and could not be attributable to the
effect of EB2 on DNA replication, since this experiment was
done using HeLa cells that were not EBV infected and by
transfection of nonreplicative plasmids.
DISCUSSION
Using a clonal population of 293 cells carrying an EBV
genome from which the EB2 gene has been deleted, we show
that upon induction of the productive cycle by transfection of
an EB1 expression vector, transcomplementation with the EB2
protein is essential for efficient nuclear export of a subpopu-
lation of EBV late mRNAs generated from intronless genes
that are translated into proteins involved in intranuclear capsid
assembly and maturation (Fig. 3). The EB2-induced increase
in the cytoplasmic accumulation of some late mRNAs is un-
likely to be due to the EB2-induced increase in the number of
intranuclear viral DNA copies (Fig. 2). Indeed, some late
mRNAs are efficiently exported in the absence of EB2, and
EB2 did not increase their cytoplasmic accumulation. More-
over, the spliced mRNAs made from the intron-containing
BLLF1 late gene were also efficiently exported in the absence
of EB2, and again EB2 had no effect on its export. Finally, the
EB2-dependent export of some late mRNAs could be repro-
duced in a transient expression assay, using nonreplicating
plasmids (Fig. 6), in line with the work of Serio et al. (40)
showing that late gene expression from EBV BcLF1 and
BFRF3 promoters does not require DNA replication in cis.
Taken together, the above-described results demonstrate that
EB2 is required for efficient nuclear export of a subpopulation
of EBV late mRNAs and that this effect is not linked to the
EB2-enhanced replication of the viral genome.
Importantly however, Ori-Lyt-replicated nuclear viral DNA
was completely digested by DNase I in the absence of EB2
(Fig. 2), demonstrating that a correct balance of expression of
proteins involved in the intranuclear capsid assembly and mat-
uration is obtained only in the presence of EB2. The correct
balance of these proteins cannot be obtained when HSV-1
ICP27 is used rather than EB2 in our transcomplementation
assay (15), demonstrating that EB2 and ICP27 are not func-
tionally equivalent in the production of EBV infectious virions.
This is in clear contrast with experimental data showing that
EB2 can complement the growth defect of an HSV-1 ICP27-
null virus, which suggested that EB2 is functionally similar to
ICP27 (3). This result is probably due to the fact that ICP27, in
contrast to EB2, inhibits splicing.
The effect of EB2 on the nuclear export of the late mRNAs
examined ranges from essential to facilitating (Fig. 3). Our
results identify some viral transcripts that are dependent on
EB2 for efficient cytoplasmic accumulation during the produc-
tive cycle. We have also looked at the nuclear accumulation of
these transcripts in the absence and presence of EB2, and we
observed that without EB2 there is no nuclear accumulation of
the viral mRNAs (data not shown). This observation is in
agreement with results obtained with HSV-1 (33), suggesting
that unexported mRNAs are degraded.
Most of the EBV late genes are intronless, but EB2 does not
export all the mRNAs generated from these intronless genes.
If some viral late mRNAs depend on EB2 to be exported, it is
evident that others such as BBRF1 (Fig. 3) and BALF4 (Fig. 4)
are efficiently exported by cellular factors, likely SR proteins
(for references, see reference 22) and/or REF (35). This is also
true for the nuclear export of HSV-1 transcripts (33). We do
not as yet know what makes an RNA a target for EB2-depen-
dent nuclear export. EB2 does not seem to bind specifically to
RNA in vitro (18) but specifically exports some but not all
EBV mRNAs. Interestingly, EB2 coimmunoprecipitates, in
vivo, with REF/Aly and TAP/NXF1 (19). As the coimmuno-
precipitation is abolished by RNase treatment (19) this could
suggest that EB2 is recruited to certain viral late mRNA nu-
cleoproteins (mRNPs) by contacting both REF and the RNA
and that the EB2-loaded viral mRNP is exported by RNA-
bound TAP/NXF1. However, it could also be that EB2 is
recruited to mRNAs by as-yet-unidentified nuclear factors but
interacts with REF and/or TAP.
Indeed, EB2 also assists in the export of mRNAs carrying
introns flanked by “ill-defined” splice sites. These include un-
spliced -thalassemia (4), in which a mutation in the first exon
5 splice site has caused the activation of three cryptic 5 splice
sites (43), pUC18 “cryptic” mRNAs (4), and the RNA export
reporter gene pDM128, which is a human immunodeficiency
virus-derived reporter gene carrying “suboptimal splice sites,”
allowing export of unspliced RNAs (9). However, these studies
have been made with artificial reporter genes, in transient
expression assays. In this study, we confirm the above-de-
scribed findings by demonstrating that when the productive
cycle is induced in cells carrying the EBV genome with the EB2
gene deleted, the unspliced EBV late BLLF1 mRNA, which is
translated into a 130-kDa protein, the precursor of the major
gp350 glycoprotein, is exported to the cytoplasm only when
EB2 is expressed by transcomplementation (Fig. 5). It is note-
worthy that in the absence of EB2, the correctly spliced BLLF1
mRNAs are exported to the cytoplasm, and EB2 has no effect
on the cytoplasmic accumulation of these spliced BLLF1
mRNAs, whereas ICP27 completely abolished the appearance
of spliced BLLF1 mRNAs in the cytoplasm, probably by in-
hibiting their splicing (38 and references therein). However,
EBV EB2, HSV-1 ICP27, and CMV UL69, even if they differ
by their effect on BLLF1-spliced mRNAs, all export unspliced
BLLF1 mRNAs (Fig. 5).
Therefore, it can be concluded that EB2 inhibits cryptic
splicing or facultative splicing and enhances export of un-
spliced mRNAs. This resembles the mechanism used by splic-
ing factors 9G8 and SRp20, which enhance the export of -glo-
bin cDNA transcripts (intronless) made from a plasmid (21).
The splicing factors 9G8 and SRp20 bind to the 22-nucleotide
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mouse histone H2a “constitutive” export element. In the ab-
sence of this element, almost all of the -globin sequences are
deleted by cryptic splicing, rendering the -globin RNA tran-
script undetectable, although the spliced transcripts are effi-
ciently exported (23). Cryptic splicing is inhibited by the export
element containing globin construct, but intron-containing
-globin mRNAs are exported (21). It could be that a deter-
minant for the nuclear export of mRNAs derived from viral
intronless genes is the inhibition of cryptic splicing and/or
recruitment of export factors like EB2 by cellular factors
bound to 5 cryptic splice sites. Confocal dual-label microscopy
and immunoprecipitation of EB2-loaded mRNPs from in-
fected cells in which the productive cycle has been induced
might allow the identification of proteins required for EB2-
mediated mRNA export.
Although our results explain why EB2 is essential for the
production of EBV infectious virions, the molecular pathways
for EB2-dependent and EB2-independent export of viral
mRNAs remain to be elucidated.
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